However, FGFR3 mutations are permissive for the development of carcinoma in situ or high-grade tumors when combined with SV40 large T antigen, PTEN loss, or the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) (19–22). The gene discussed is FGFR3; the disease is cancer.